Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The filing details a specific transaction on February 21, 2011, involving Dr. M. M. Slaoui, a Person Discharging Managerial Responsibility. A connected person employed by the Company sold 244 Ordinary shares (ADSs) at a price of $39.15 per share. Following this sale, 396 shares were retained. The transaction was executed to meet tax liabilities following the vesting of a Share Value Plan award.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to Disclosure and Transparency Rule 3.1.4R(1)(c) regarding the notification of the aforementioned share transaction.
Investor Verification Points
- Verify the share price of $39.15 per Ordinary share ADR on February 21, 2011.
- Confirm the total number of shares retained (396) by the connected person post-transaction.
- Review the specific terms of the Share Value Plan award that triggered the tax liability.